The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research and the development of better diagnostic tools, which may improve the disease prognosis. Additionally, the launch of emerging therapies such as LOAd703 (Lokon Pharma), Daraxonrasib (Revolution Medicines), BNT122 (BioNTech/Genentech), OT-101 (Oncotelic), ELI-002 (Elicio Therapeutics), and others will further propel the market.
DelveInsight'sPancreatic Cancer Market Insightsreport includes a comprehensive understanding of current treatment practices, pancreatic canceremerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Pancreatic Cancer Market Summary
— The market size for pancreatic cancerin the leading markets is expected to grow significantly by 2034.
— The United States accounted for the highest pancreatic cancertreatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
— The total number of incident cases of pancreatic cancer in the US was approximately 63K in 2024.
— Leading pancreatic cancercompanies developing emerging therapies, such as Lokon Pharma, Oncotelic, Revolution Medicines, Novocure, BioNTech, Genentech, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Tyligand Pharmaceuticals (Suzhou), Jacobio Pharmaceuticals, and others, are developing new therapy for pancreatic cancerthat can be available in the pancreatic cancermarket in the coming years.
— The promising pancreatic cancertherapies in clinical trials include LOAd703, OT-101, Daraxonrasib, Optune, BNT122, ELI-002, HRS-4642, TSN1611, Glecirasib, and others.
Discover the pancreatic cancer new treatment @ New Treatments for Pancreatic Cancer
Key Factors Driving the Growth of the Pancreatic Cancer Market
Rising Pancreatic Cancer Incidence
Increasing incidence rates of pancreatic cancer globally, driven by the aging population and rising prevalence of risk factors such as obesity, diabetes, smoking, and alcohol consumption, are driving the pancreatic cancer market. According to DelveInsight's analysis, the total number of incident cases of pancreatic cancer in the US was ~63K in 2024. These numbers are further expected to increase by 2034.
Role of Immune Checkpoint Inhibitors in PDAC
The potential of immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies, is being explored in PDAC. Clinical trials combining immunotherapy with other treatment modalities (e.g., chemotherapy, radiation, or targeted therapies) may increase efficacy and open new treatment pathways.
Advancing Precision Medicine for Pancreatic Cancer
Novel strategies, including RAS-directed therapies and advanced immunotherapies, are being developed to more effectively tackle pancreatic cancer. These approaches offer hope for improved survival and quality of life by targeting cancer more precisely.
Advancing PDAC Treatment Through Targeted and Combination Approaches
The development of new targeted therapies, such as KRAS inhibitors (like Daraxonrasib) or epigenetic modulators, provides an opportunity to treat PDAC based on specific genetic mutations or tumor characteristics. Additionally, combination therapies, which pair existing treatments with newer agents, offer an opportunity to overcome resistance and enhance therapeutic effectiveness.
Emergence of Novel Pancreatic Cancer Drugs
The pancreatic cancer treatment pipeline for metastatic or unresectable pancreatic cancer includes LOAd703 (Lokon Pharma), OT-101 (Oncotelic), Daraxonrasib (Revolution Medicines) (first-line treatment), and Optune (Novocure). In the adjuvant or neoadjuvant setting, therapies under development include Daraxonrasib for resectable PDAC, BNT122 (BioNTech and Genentech), and ELI-002 (Elicio Therapeutics) for patients with high relapse-risk mKRAS+ PDAC.
Emerging KRAS-Targeted Therapies in Pancreatic Cancer
There are multiple KRAS-targeting drugs in development for pancreatic cancer, including HRS-4642 (Jiangsu Hengrui Pharmaceuticals) (with gemcitabine/nab-paclitaxel) for neoadjuvant/adjuvant use, TSN1611 (Tyligand Pharmaceuticals (Suzhou)) for KRAS G12D-mutated tumors, Glecirasib (Jacobio Pharmaceuticals) (JAB-21822) for KRAS G12C-mutated advanced cancers, and others.
Pancreatic Cancer Market Analysis
Pancreatic cancer management remains highly challenging and depends on the stage of the disease. Treatment typically involves a multimodal strategy that combines surgery, chemotherapy, and radiation, while novel targeted therapies are beginning to show encouraging results in molecularly defined patient groups.
Because pancreatic cancer exhibits low immunogenicity, it is often classified as an immunologically “cold” tumor. This characteristic implies that successful immunotherapy will likely require activating multiple steps of the cancer-immunity cycle to counter immune evasion and elicit a strong antitumor response.
The FDA has approved several targeted agents for pancreatic cancer, including LYNPARZA (olaparib; AstraZeneca), VITRAKVI (larotrectinib; Bayer), ROZLYTREK (entrectinib; Genentech), KEYTRUDA (pembrolizumab; Merck), and BIZENGRI (zenocutuzumab; Merus and Partner Therapeutics).
At present, the pancreatic cancer treatment landscape is largely driven by first-line therapies, with limited utilization of neoadjuvant and adjuvant options. However, this scenario is expected to shift as a strong pipeline emerges, focused on key molecular targets such as KRAS, BRCA, and NRG1. Notable candidates, such as Daraxonrasib and OT-101, highlight ongoing innovation in targeted approaches.
Furthermore, HOIST is developing two promising investigational therapies: HM-001, aimed at treating carcinomatous peritonitis and peritoneal dissemination, and an ALKBH3 inhibitor that targets disease progression through the ALKBH3 gene. Preclinical studies in pancreatic cancer patient-derived xenograft (PDX) models have demonstrated that subcutaneous administration of an ALKBH3 inhibitor achieves efficacy comparable to that of gemcitabine. Collectively, these developments underscore the growing potential of targeted therapies in addressing the unmet needs of pancreatic cancer treatment.
To know more about pancreatic cancer treatment options, visit @ Approved Pancreatic Cancer Drugs
Pancreatic Cancer Competitive Landscape
Emerging drugs for pancreatic cancer treatment include LOAd703 (Lokon Pharma), Daraxonrasib (Revolution Medicines), BNT122 (BioNTech/Genentech), OT-101 (Oncotelic), ELI-002 (Elicio Therapeutics), and others.
Revolution Medicines' Daraxonrasibis an oral, multi-selective RAS(ON) inhibitor designed to form a tri-complex that targets multiple active RAS variants harboring oncogenic mutations across the three major RAS hotspot positions. By inhibiting all key RAS isoforms, it suppresses both mutant cancer-driving and cooperating wild-type RAS proteins. The therapy is currently under investigation in the Phase III RASolute-302 trial (NCT06625320) for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results anticipated in 2026.
BioNTech/Genentech's BNT122, an individualized mRNA-based cancer vaccine developed in collaboration with Genentech, aims to generate neoantigen-specific immune responses. It is being tested in a Phase II trial (NCT05968326) in combination with atezolizumab, followed by standard-of-care chemotherapy (mFOLFIRINOX) for patients with resected PDAC, compared to chemotherapy alone. In February 2025, long-term follow-up data from the Phase I PDAC study were published in Nature.
Novocure's Optuneis a therapeutic device that employs Tumor Treating Fields (TTFields)-low-intensity, alternating electric fields that disrupt cancer cell division through multiple physical mechanisms. Due to its multimodal mechanism, TTFields therapy can be integrated with existing treatments, such as chemotherapy, radiotherapy, immunotherapy, or targeted therapy, thereby enhancing efficacy across various solid tumor types in preclinical studies.
Oncotelic's OT-101 (trabedersen)is a novel phosphorothioate antisense oligodeoxynucleotide that targets TGF-B2 mRNA. Demonstrating encouraging outcomes in early clinical studies, OT-101 is now being assessed in Phase II/III (STOP-PC, NCT06079346) trials in combination with mFOLFIRINOX for patients with advanced, unresectable, or metastatic pancreatic cancer.
The anticipated launch of these emerging therapies are poised to transform the pancreatic cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the pancreatic cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for pancreatic cancer @ Pancreatic Cancer Clinical Trials
Recent Developments in the Pancreatic Cancer Market
— In September 2025, Revolution Medicines announced key clinical updates from its Phase I trials of daraxonrasib, supporting the initiation of RASolute-303, a global Phase III registrational study evaluating daraxonrasib as a first-line treatment for metastatic PDAC.
— In August 2025, Novocure submitted a Premarket Approval (PMA) application to the US FDA for its Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. The submission is supported by data from the Phase III PANOVA-3 trial, with an FDA approval decision anticipated in the second half of 2026.
— In June 2025, Revolution Medicines announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to daraxonrasib for previously treated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in patients with KRAS G12 mutations.
— In May 2025, Novocure presented positive results from the Phase III PANOVA-3 clinical trial, which evaluated the use of TTFields therapy in combination with gemcitabine and nab-paclitaxel for locally advanced, unresectable pancreatic adenocarcinoma, at the American Society of Clinical Oncology (ASCO) 2025.
— In March 2025, the FDA granted PEP-010, a first-in-class bi-functional therapeutic peptide, Orphan Drug Designation (ODD) for the potential treatment of patients with metastatic pancreatic cancer.
What is Pancreatic Cancer?
Pancreatic cancer is a malignant disease that originates in the tissues of the pancreas, an organ situated behind the stomach that plays a crucial role in digestion and blood sugar regulation. Most pancreatic cancers start in the ducts that carry digestive enzymes, known as pancreatic ductal adenocarcinoma (PDAC), which is the most common and aggressive form. Because the disease often develops silently and symptoms such as jaundice, abdominal pain, weight loss, or fatigue typically appear only in advanced stages, it is frequently diagnosed late. This late detection contributes to its poor prognosis and high mortality rate. Risk factors include smoking, chronic pancreatitis, obesity, diabetes, and a family history of the disease. Early detection and advancements in targeted therapy and immunotherapy are crucial areas of ongoing research aimed at improving survival outcomes for pancreatic cancer patients.
Pancreatic Cancer Epidemiology Segmentation
The pancreatic cancer epidemiology section provides insights into the historical and current pancreatic cancer patient pool and forecasted trends for the leading markets. As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer, accounting for more than 90% of total cases.
The pancreatic cancer market reportproffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
— Total Incident Cases of Pancreatic Cancer
— Stage-specific Cases of Pancreatic Cancer
— Type-specific Cases of Pancreatic Cancer
— Age-specific Cases of Pancreatic Cancer
— Molecular Alteration-specific Cases of Pancreatic Cancer
— Total Treated Cases of Pancreatic Cancer by Line of Therapy
Scope of the Pancreatic CancerMarket Report
— Therapeutic Assessment: Pancreatic Cancercurrent marketed and emerging therapies
— Pancreatic CancerMarket Dynamics:Key Market Forecast Assumptions of Emerging Pancreatic Cancer Drugs and Market Outlook
— Competitive Intelligence Analysis:SWOT analysis and Market entry strategies
— Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement
Download the report to understand which factors are driving pancreatic cancer therapeutics markettrends@Pancreatic Cancer Market Trends
Table of Contents
Related Reports
Pancreatic Cancer Clinical Trial Analysis
Pancreatic Cancer Pipeline Insight -2025report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic cancer companies, including Erytech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical, Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, among others.
Metastatic Pancreatic CancerMarket
Metastatic Pancreatic CancerMarket Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Eli Lilly and Company, Salspera LLC, Bristol Myers Squibb, Cantex Pharmaceuticals, Ocuphire Pharma, Merrimack Pharmaceuticals, Infinity Pharmaceuticals, FibroGen, ImmunityBio, Sanofi, among others.
Advanced Pancreatic Cancer Market
Advanced Pancreatic CancerMarket Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others.
Metastatic Pancreatic Cancer Clinical Trial Analysis Pipeline
Metastatic Pancreatic Cancer Pipeline Insight -2025report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, includingJiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, among others.
AboutDelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.
Contact UsShruti Thakur info@delveinsight.com +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=IO43299&sd=2025-12-10
View original content:https://www.prnewswire.com/news-releases/pancreatic-cancer-market-set-to-expand-during-the-forecast-period-20252034-as-precision-medicine-and-immunotherapy-transform-treatment-landscape–delveinsight-302637673.html
SOURCE DelveInsight Business Research, LLP
https://rt.newswire.ca/rt.gif?NewsItemId=IO43299&Transmission_Id=202512101731PR_NEWS_USPR_____IO43299&DateId=20251210